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Abstract
Alzheimer’s disease (AD) is characterized by progressive dysfunction of memory
and higher cognitive functions with abnormal accumulation of extracellular amyloid
plaques and intracellular neurofibrillary tangles throughout cortical and limbic brain
regions. Withania somnifera (WS) also known as ‘ashwagandha’ (ASH) is used
widely in Ayurvedic medicine as a nerve tonic and memory enhancer. However,
there is paucity of data on potential neuroprotective effects of ASH against bAmyloid (1–42) (Ab) induced neuropathogenesis. In the present study, we have
tested the neuroprotective effects of Methanol: Chloroform (3:1) extract of ASH and
its constituent Withanolide A (WA) against Ab induced toxicity, HIV-1Ba-L (clade B)
infection and the effects of drugs of abuse using a human neuronal SK-N-MC cell
line. Ab when tested individually, induced cytotoxic effects in SK-N-MC cells as
shown by increased trypan blue stained cells. However, when ASH was added to
Ab treated cells the toxic effects were neutralized. This observation was supported
by cellular localization of Ab, MTT formazan exocytosis, and the levels of
acetylcholinesterase activity, confirming the chemopreventive or protective effects
of ASH against Ab induced toxicity. Further, the levels of MAP2 were significantly
increased in cells infected with HIV-1Ba-L (clade B) as well as in cells treated with
Cocaine (COC) and Methamphetamine (METH) compared with control cells. In
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ASH treated cells the MAP2 levels were significantly less compared to controls.
Similar results were observed in combination experiments. Also, WA, a purified
constituent of ASH, showed same pattern using MTT assay as a parameter. These
results suggests that neuroprotective properties of ASH observed in the present
study may provide some explanation for the ethnopharmacological uses of ASH in
traditional medicine for cognitive and other HIV associated neurodegenerative
disorders and further ASH could be a potential novel drug to reduce the brain
amyloid burden and/or improve the HIV-1 associated neurocognitive impairments

Introduction
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease affecting
approximately 36 million people worldwide [1] and if the current trend continues
without medical innovation, one in 85 people will be affected with AD by 2050
[2]. Considerable attention has been focused on the deposition of insoluble bamyloid peptide (Ab) within the brain as a major etiologic factor in the
pathogenesis of AD which is characterized by a decline in cognitive functions, for
example memory loss, language deficit associated with behavioral and
psychological symptoms like depression, stress, anxiety and mental upset [3, 4].
Pathological hallmarks include toxic b-amyloid plaques, neurofibrillary tangles,
dystrophic neuritis, gliosis, decline of neurochemicals which are essential for
neuronal transmission and neuroinflammation [5–7]. The Ab cytotoxicity to
neuronal cells has been identified as one of the major features in AD pathology,
but the exact mechanisms involved leading to neurotoxicity still remain an
enigma [8, 9]. A widely recognized concept about AD pathogenesis is the
‘‘amyloid hypothesis,’’ whereby augmented production and self-assembly of Ab
toxic constituents begins a sequence of advancing alterations that eventually lead
to neuronal degeneration [10–13]. In this hypothesis, continuous Ab toxicity
associated stress activates the hyper-phosphorylation and aggregation of the
microtubule-associated protein tau, resulting in neurofibrillary tangles, which are
a major pathological hallmark of AD [12]. Accordingly, a better understanding of
the mechanisms that are associated with the generation, accumulation and
clearance of Ab might represent a promising therapeutic approach for the
treatment of AD. Neuronal degeneration is also a major feature in HIV infection
and AIDS. Specifically, increased amyloid-b precursor protein (AbPP) in axons in
the subcortical white matter tracts have been described by several investigators
[14–16]. It has been reported that HIV persists in the brain during HAART
therapy and that the local inflammatory responses to HIV in the brain could lead
to increased AbPP production and susceptibility to Ab deposition [17]. All these
observations indicate that Ab accumulation may be a good indicator of early
neuronal (axonal) degeneration not only during the development of AD but also
during HIV induced neuronal degeneration.
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Withania somnifera (WS) ‘‘also known as ‘ashwagandha’ (ASH) in Sanskrit’’ is
a multipurpose medicinal plant which has been used in a remarkable number of
pharmacological studies in recent years, as it has been shown to possess a wide
spectrum of therapeutic properties such as nerve tonic, memory enhancer,
antistress, immunomodulatory and antioxidant properties [18, 19]. Withanolide
A and withanoside IV from roots help to promote neurite outgrowth in cultured
neurons and in rodents injected with Ab 25–35 [20]. Root extracts from this
species have also been shown to significantly reduce the number of hippocampal
degenerating cells in the brains of stressed rodents [21] and were neuro-protective
in animal models of Parkinson’s disease [22]. A recent study of oral
administration of a semi-purified extract of the root of ASH consisting
predominantly of withanolides and withanosides reversed behavioral deficits,
plaque pathology, accumulation of Ab and oligomers in the brains of middle-aged
and old APP/PS1 Alzheimer’s disease transgenic mice [23]. However, there is a
paucity of data on the molecular mechanisms associated with the potential
protective effects of ASH root, as used traditionally, against Ab-induced
cytotoxicity and associated neuronal degeneration. Accordingly, we hypothesized
that it will be of great interest to use ASH to reverse the neuronal toxicity induced
by Ab which may serve as a potential therapeutic agent for use in AD and possibly
in other HIV related disorders involving memory deficiency. We have reported
that Ab induced cytotoxic effects in SK-N-MC cells when tested individually,
however, when ASH was added to Ab treated cultures, the cytotoxic effects of Ab
were neutralized [24]. In the present research, we wish to report that ASH and its
constituent, Withanolide A (WA) can, not only prevent Ab induced cytotoxicity
and cell death, cellular localization, MTT formazan exocytosis and inhibition of
acetylcholinesterase activity but also protect against HIV infection and
neurodegenerative effects of substance abuse, indicating the neuroprotective
properties.

Materials and Methods
Cell Culture
The effects of Ab and ASH were tested on the human neuronal cell line, SK-NMC, obtained from American Type Culture Collection (ATCC) (Catalog # HTB10; Manassas,VA). The cells were grown in T-75 flasks containing Eagle’s
minimum essential medium (MEM) (GIBCO) with fetal bovine serum to a final
concentration of 10% and 1% antibiotic/antimycotic solution. The cells were
maintained in a humidified, 95% air and 5% CO2 atmosphere incubator at 37 ˚C.

Fibrillar b-Amyloid1–42 (Ab1–42) or ‘‘seed’’ preparation
Fibrillar Ab1–42 was prepared as described by Wogulis et al [25]. One mg of Ab1–42
lyophilized powder (Catalog # A9810, Sigma-Aldrich) was dissolved in 200 ml of
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water in glass vial and aged for 3 days at 37 ˚C and was diluted with tissue culture
medium to the required concentration, before adding to neuronal cultures.

Extracts of Withania somnifera roots
The dried roots of ASH were purchased from an authenticated source in Kerala,
India (Arya Vaidya Sala, Kottakal). The ground powder (15 g) was suspended in
300 ml of solvents (Methanol: Chloroform) (3:1), refluxed for 3 hr. and the
supernatant collected. The residue was again suspended in 300 ml of same solvent
and refluxed for another 3 hr. and the supernatant collected. Both the
supernatants were combined, filtered to remove insoluble material and
concentrated to dryness using a rotary vacuum evaporator. The dried extract was
solubilized in dimethylsulfoxide (DMSO), aliquoted, stored at 220 ˚C and utilized
for all experiments. Analysis and identification of this dried extract using positive
ion LS-MS showed the presence of Withanolide A as the major constituent,
identified against a standard [24]. Besides Withanolide A, presence of some minor
components was also observed [24]. Further studies are required to identify these
components and their biological significance.

Analysis of cell death in Ab treated cultures
Cell death assays using logarithmically-growing cells were performed using the
previously described protocol [26] with slight modifications. In brief, SK-N-MC
cells were grown onto 22 mm 622 mm glass coverslips at a concentration of
0.16106 in 3 ml of culture medium in 6-well plates for 48 hours and after that
changed to 1 ml of serum free medium. ASH was added at 0.16 mg/ml to plain
ASH control and Ab plus ASH cultures. For ASH additions, DMSO served as the
vehicle to dilute the compound at a final concentration of 0.4% volume per
volume and at this concentration has no effect on cell survival. Control cultures
received only solvent in the place of test compound. Three hours after preincubation of cells with ASH, Ab and Ab plus ASH cultures received Ab at a
concentration of 5 mM. Different investigators have used different dose levels of
Ab depending on the cell type utilized. Michaelis et al [27] used 5 and 10 mM
concentration on cortical cell cultures whereas Yankner et al [28] used 20 mM on
hippocampal neurons. Kumar et al [29] utilized 0.007-2 mg/mL concentration on
PC12 cell line and London et al [30] 0.2, 2.0 and 20 mM on peripheral blood
monocytes (PBM). We have standardized the doses required for our studies by
testing at different doses and selecting a dose of about 40% inhibition and used for
all our experiments [24]. After 24 hours, 10 ml of 0.4% Trypan Blue (GIBCO)
stain solution were added to the culture medium of cells. After 15 min cells were
washed with PBS and glass coverslips with cells were mounted on slides in
glycerol/distilled water (1:1) plus 0.1% sodium azide (Sigma-Aldrich) and the cells
were examined under a microscope using an objective 406 (400x magnification)
and photographed to detect stained cells.
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Internalization of Ab

1–42

determined by Congo red staining

Same protocol described above was utilized for culture conditions, addition of
ASH and Ab and exposure time. After the culture period the cells were washed
with PBS, fixed in 4% formalin for 15 min at room temperature. Again cells were
washed with PBS and then stained with a fresh alkaline solution of 0.5% filtered
Congo red (Sigma-Aldrich) at room temperature for 5 min. After several washes
with deionized water, slides were mounted in glycerol/distilled water (1:1) plus
0.1% sodium azide (Sigma-Aldrich) and then observed under a microscope using
an objective 406 (400x magnification) and photographed to detect stained cells.

MTT Formazan Exocytosis
Same protocol described above for analysis of cell death was utilized for culture
conditions, addition of ASH and Ab and exposure time. After the culture period
100 ml of MTT (100 mg MTT/20 ml PBS) were added for each well and incubated
at 37 ˚C for 2 hours. After that cells were washed with PBS and glass coverslips
with cells were mounted on slides in glycerol/distilled water (1:1) plus 0.1%
sodium azide (SIGMA-ALDRICH) and the cells were examined under a
microscope using an objective 406 (400x magnification) and photographed to
detect MTT formazan exocytosis. The needle-like crystals on the surface of the
cells treated with only Ab, which are easily visible under a light microscope,
represent exocytosed MTT formazan [31, 32].

Acetylcholinesterase Activity
Determination of the acetylcholinesterse activity was carried out as per the
method of Vinutha et al [33] with some modifications. In brief, cells were
harvested from exponential phase cultures by trypsinisation, counted and plated
in 96-well flat-bottomed microtitre plates at a seeding density of 36104 in 200 ml
of medium for 24 hours and after that changed to 200 ml of serum free medium.
ASH was added at 0.16 mg/ml to plain ASH control and Ab plus ASH cultures.
For ASH additions, DMSO served as the vehicle to dilute the compound at a final
concentration of 0.4% volume per volume and at this concentration has no effect
on cell survival. Control cultures received only solvent in the place of test
compound. Three hours after pre-incubation of cells with ASH, Ab and Ab plus
ASH cultures received Ab at a concentration of 5 mM. After 48 hours, the
medium was removed and a pre-incubation volume of 250 ml of phosphate buffer
(200 mM, pH 7.7) containing 80 ml of DTNB (3.96 mg of DTNB and 1.5 mg of
sodium bicarbonate dissolved in 10 ml of phosphate buffer, pH 7.7) was added to
the cultures and incubated at room temperature for 5 min. Following preincubation, 15 ml of substrate (10.85 mg of acetylthiocholine iodide dissolved in
5 ml of phosphate buffer, pH 7.7) was added and incubated at 37 ˚C for one hour.
The enzyme acetylcholinesterase of the cells releases thiocholine from acetylthiocholine which reacts with dithiobisnitrobenzoic acid to produce yellow color
which was measured in a microwell plate reader at 412 nm. The optical density of
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the yellow color is directly proportional to the enzyme activity and utilized for
calculation of percent values.

Effects of ASH on HIV-1 infection and drugs of abuse and Western
blot analysis
SK-N-MC (16106) cells were cultured in T-75 flasks in 10 ml complete medium
for 48 hours and after that changed to 10 ml of fresh complete medium and
polybrene (5 mg/ml) was added for 8 hours. After that cells were infected with
100 ng of HIV-1Ba-L (clade B) (NIH AIDS Reagent Program, Cat. # 510)
overnight in respective flasks as described earlier [24]. Next day morning, cells
were washed with PBS to remove unattached virus and replaced with fresh 10 ml
medium and/or treated with drugs of abuse and ASH. The groups included are 1)
Plain Controls, 2) HIV-1 Infected, 3) Cocaine Treated (100 nM), 4)
Methamphetamine (METH) Treated (25 mM), 5) ASH was added at 0.16 mg/ml
to plain ASH controls, 6) HIV-1+ ASH, 7) Cocaine + ASH, 8) METH + ASH, 9)
HIV-1 + Cocaine + ASH and 10) HIV-1 + METH + ASH. For ASH additions,
DMSO served as the vehicle to dilute the compound at a final concentration of
0.4% volume per volume and at this concentration has no effect on cell survival.
Control cultures received only solvent in the place of test compound. For
combination of HIV-1, ASH and drug effects, same concentrations in
combination were utilized. The cells were cultured with additions for 48 hours
and after that cells were washed with PBS solution and were harvested using
Trypsin/EDTA solution (ScienceCell Laboratories), cell pellets were collected and
lysed using lysis buffer (Pierce, IL) with 1x complete cocktail of protease
inhibitors. Total cellular protein in equal quantity was resolved by 4–15%
polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane. The
following primary antibodies were used: anti-MAP2 (Cell Signaling Technology,
Cat # 4542) and anti-GAPDH (Santa Cruz Biotechnology). Immunoreactive
bands were visualized using a chemiluminescence’s Western blotting system
according to the manufacturer’s instructions (Amersham). The supernatant
obtained from the used medium was used for the p24 antigen estimation using
ELISA kit (ZeptoMetrix Corp. Cat # 0801200).

MTT Cell Viability Assay
The MTT cell viability assay was carried out by the modified assay as described by
Kurapati et al. [24]. After the culture period, media was removed from the 6-well
plates and one ml of PBS was added. A solution of 100 ml of MTT (100 mg MTT/
20 ml PBS) was added for each well and incubated at 37 ˚C for 3 hours. After that,
one volume of stop mix solution (20% SDS in 50% N, N-Dimethylformamide)
was added and rocked for about 2 hours and the optical density of the solubilized
formazan was determined spectrophotometrically measuring the absorbance at
550 nm. The optical density of formazan in each well is directly proportional to
the cell viability and utilized for calculations.
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Dose response curve and Neuroprotective effects of Withanolide A
(WA)
The SK-N-MC (36103) cells obtained from sub-confluent flasks were cultured in
6-well plates in 2 ml complete medium for 48 hours and after that media were
removed and equal volume of fresh medium was added. WA (Cat # W2145,
Sigma-Aldrich) was added at different concentrations in 8 ml volumes and
cultured for another 48 hours. For WA additions, DMSO served as the vehicle to
dilute the compound at a final concentration of 0.4% volume per volume and at
this concentration has no effect on cell survival. Control cultures received only
solvent in the place of test compound. After the culture period, cells were utilized
for MTT assay as described above. The neuroprotective effects of WA were
performed using the previously described protocol [24]. SK-N-MC cells were
grown at a concentration of 36103 in 2 ml of culture medium in 6-well plates for
48 hours and after that changed to 1 ml of serum free medium. WA was added at
two doses of 10 mg/ml and 20 mg/ml to plain WA control and b-amyloid plus WA
cultures. Control cultures received only solvent in the place of test compound.
Three hours after pre-incubation of cells with WA, Ab and Ab plus WA cultures
received Ab at a concentration of 5 mM [24]. After 24 hours, cells were utilized for
MTT assay as described above.

Effects of WA on HIV-1 infection and drugs of abuse and MTT
assay
SK-N-MC (36103) cells were cultured in 6-well plates in 2 ml complete medium
for 48 hours and after that changed to 2 ml of fresh complete medium and
polybrene (5 mg/ml) was added for 8 hours. After that, cells were infected with
25 ng of HIV-1Ba-L (clade B) (NIH AIDS Reagent Program, Cat. # 510) overnight
as described earlier [24]. Next day morning, cells were washed with PBS to remove
unattached virus and replaced with fresh 2 ml medium and/or treated with drugs
of abuse and WA. The groups included are 1) Plain Controls, 2) HIV-1 Infected,
3) Cocaine Treated (100 nM), 4) Methamphetamine (METH) Treated (25 mM),
5) WA was added at 20.0 mg/ml to plain WA controls, 6) HIV-1+ WA, 7) Cocaine
+ WA, 8) METH + WA, 9) HIV-1 + Cocaine + WA and 10) HIV-1 + METH +
WA. For WA additions, DMSO served as the vehicle to dilute the compound at a
final concentration of 0.4% volume per volume and at this concentration has no
effect on cell survival. Control cultures received only solvent in the place of test
compound. For combination of WA, HIV-1 and drug effects, same concentrations
in combination were utilized. The cells were cultured with additions for 48 hours
and after that media removed and cells were washed with PBS solution and were
utilized for MTT assay as described above. The supernatant obtained from the
used medium was used for the p24 antigen estimation using ELISA kit
(ZeptoMetrix Corp. Cat # 0801200).
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Statistical Analysis
The results are expressed as mean ¡ standard deviation and the significance was
evaluated using the Student’s t-test (GraphPad Software, CA, USA). Results giving
p#0.02 were considered significant.

Results
Chemoprevention has been acknowledged as an important and practical strategy
for the management of several disorders. From this point of view, we have selected
root extract of ASH, which is in common use in Indian traditional medicine to
promote cognition, including memory. The major chemical constituents of the
roots are withanolides, particularly WA, although the mechanism by which WS
root accomplishes these activities is still largely unknown. Accordingly, the root
powder was extracted with a mixture of methanol: chloroform (3:1) for testing the
beneficial effects on SK-N-MC, a neuronal cell line. We have also tested its
purified constituent WA. This extract [24] and its purified product WA showed
growth stimulatory effects on SK-N-MC cell line and accordingly was used for all
our studies.

Analysis of cell death in Ab treated cultures
The trypan blue staining of untreated SN-N-MC cells showed mostly viable cells
with very few trypan-positive cells (Fig.1A). In contrast, the plain Ab treated
cultures stained significant number of trypan-positive cells (Fig.1B) suggesting
that Ab treatment promoted cell degeneration and death compared to plain
controls. However, when ASH was added to Ab treated cultures, the cytotoxic
effects of Ab were neutralized (Fig.1D) and the cells were comparable to plain
(Fig.1A) and ASH (Fig.1C) treated controls, indicating the chemopreventive or
protective effects of ASH against Ab induced toxicity.

ASH decreases the internalization of Ab

1–42

In order to understand the effect of ASH on the internalization of Ab in SK-NMC cells, cells were pre-incubated with the extract for three hours and then
exposed to Ab for 24 hours. After that, cells were stained with Congo red, a
metachromatic anionic dye, specific for Ab. As Fig.2 shows, cultures treated with
Ab alone (Fig.2B) showed much more marked internalization of the toxic peptide
than occurred when cells were incubated with Ab plus ASH (Fig.2D). Plain
controls (Fig.2A) and ASH (Fig.2C) treated cultures showed only back ground
staining.

MTT Formazan Exocytosis by b-Amyloid Treatment
When viable cells are incubated with the tetrazolium salt MTT, they reduce the
salt to a purple water-insoluble formazan. Reduction of MTT in cells is regarded

PLOS ONE | DOI:10.1371/journal.pone.0112818 November 21, 2014
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Figure 1. Analysis of b-Amyloid toxicity and its reversal by Ashwagandha. Untreated, ashwagandha and
ashwagandha plus b-Amyloid treated cells exhibited good viability as evidenced by exclusion of trypan blue
dye, contrary to the positive trypan blue staining of SK-N-MC cells treated with b-Amyloid. A. Control, B. bAmyloid 1-42 treated, C. Ashwagandha treated and D. Ashwagandha plus b- Amyloid1-42 treated. Scale bar:
100 mm. Experiment was repeated three times.
doi:10.1371/journal.pone.0112818.g001

as an indicator of ‘‘cell redox activity’’ and the reaction is attributed mainly to
mitochondrial enzymes besides number of non-mitochondrial enzymes present in
the endoplasmic reticulum, cytosol and plasma membranes. When examined
under a microscope, formazan granules of reduced MTT are confined to different

Figure 2. Congo red staining showing the increased internalization in b- Amyloid1-42 treated and its
reversal by Ashwagandha in SK-N-MC cell line. A. Control, B. b- Amyloid 1-42 treated, C. Ashwagandha
treated and D. Ashwagandha plus b- Amyloid1-42 treated. Scale bar: 100 mm. Experiment was repeated three
times.
doi:10.1371/journal.pone.0112818.g002
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Figure 3. Effect of b-Amyloid toxicity on the appearance of needle-like MTT formazan exocytosis and
its reversal by Ashwagandha. Untreated, ashwagandha and ashwagandha plus b-Amyloid treated cells
showed even intracellular distribution of formazan crystals, contrary to the MTT formazan exocytosis and
needle-like formazan crystals on the cell surface of SK-N-MC cells treated with b-Amyloid. A. Control, B. bAmyloid 1-42 treated, C. Ashwagandha treated and D. Ashwagandha plus b- Amyloid1-42 treated. Scale bar:
100 mm. Experiment was repeated three times.
doi:10.1371/journal.pone.0112818.g003

intracellular organelles. However, in cells treated with Ab, needle-like formazan
crystals begin to appear on the cell surface, which are the exocytosed MTT
formazan [32] and clearly visible under the light microscope. The effect of MTT
cellular reducing activity on the images of morphological characteristics and
architecture in Ab (Fig. 3B) as well as Ab plus ASH (Fig.3D) and control (Fig.3A)
and only ASH (Fig.3C) treated SK-N-MC cells were captured using light
microscopy. Treatment of SK-N-MC cells with Ab resulted in significant increase
in MTT formazan exocytosis and needle-like formazan crystals on the cell surface
(Fig.3B) compared with the even intracellular distribution in untreated control
cells (Fig.3A). Also, both ASH (Fig.3C) and ASH plus Ab (Fig.3D) treated cells
showed no formazan exocytosis and were comparable with untreated control
(Fig.3B).

Increased Acetylcholinesterase Activity in b-amyloid treated
cultures and its reversal by ashwagandha
It is known that one of the characteristic alterations that occur in Alzheimer’s
disease is the loss of acetylcholinesterase (AChE) activity, the enzyme that is
responsible for acetylcholine hydrolysis, from both cholinergic and noncholinergic neurons of the brain. However, AChE activity has been shown to be
increased within and around amyloid plaques to promote the assembly of amyloid
beta-peptides into fibrils and to increase the cytotoxicity of these peptides
suggesting that AChE could play a pathogenic role in AD by influencing the
process leading to amyloid toxicity. Therefore, in order to understand the role of
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Figure 4. Increased acetylcholinesterase activity by b-Amyloid and its reversal by ashwagandha. The
values were expressed as percentage of acetylcholinesterase activity in control cells and are the mean ¡ SD
of five experiments. *** indicates a statistically significant difference compared to controls (p,0.0001). ASH Ashwagandha; AMY - b-amyloid.
doi:10.1371/journal.pone.0112818.g004

AChE during the exposure of Ab as well as in the combination of Ab plus ASH,
acetylcholinesterase activity was determined in cells after exposure. The activity of
AChE, the enzyme responsible for the acetylcholine degradation was significantly
increased (p,0.0001) in cells treated with Ab (0.267¡0.011) compared with the
untreated control cells (0.17¡0.15) (Fig.4). In ASH controls and as well as ASH
plus Ab treated cells, the AChE activity was not different compared to untreated
control (Fig.4).

Increased MAP2 protein levels in HIV-1 infected and drugs of
abuse treated cultures and their reversal by ASH
Microtubule-associated protein 2 (MAP2) is a marker of neuronal differentiation
that regulates the structure and stability of microtubules. Dynamic instability of
microtubules is critical for mitotic spindle assembly and disassembly during cell
division, especially in rapidly dividing cells. Microtubule-associated proteins
(MAPs) are a family of proteins that influence this property. MAP2 stabilizes
microtubules and that disrupts the dynamic instability of microtubules which
inhibit cell division. It has been reported that in metastatic melanoma cell lines
MAP2 expression induces microtubule stabilization, cell cycle arrest in G2-M
phase and growth inhibition. Further, disruption of microtubule dynamics by
MAP2 resulted in multipolar mitotic spindles, defects in cytokinesis and
accumulation of cells with large nuclei [34]. This suggests the possible pathogenic
role of MAP2 in neurodegeneration due to its increased levels. Accordingly, in
order to understand the neurodegenerative role of MAP2 during HIV-1 infection
and as well as during the exposure to drugs of abuse and their possible reversal by
ASH, MAP2 levels were determined in cells after their exposure by Western
blotting. The levels of MAP2 were significantly increased in cells infected with
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Figure 5. Western blotting analysis showing the increased MAP2 protein levels in HIV-1Ba-L (clade B),
Cocaine and METH treated and their reversal by Ashwagandha in SK-N-MC neuronal cells. (A) Cell
lysates were separated in 4% to 15% linear gradient SDS-PAGE gels and were probed against the respective
antibodies. GAPDH was used as the loading control. (B) Quantitative analysis showing the increased MAP2
protein levels in HIV-1Ba-L (clade B), Cocaine and METH treated and their reversal by Ashwagandha. The gel
shown is a representative for three experiments.
doi:10.1371/journal.pone.0112818.g005

HIV-1and as well as in cells treated with Cocaine and METH compared with the
untreated control cells (Fig.5). In plain ASH treated cells the MAP2 levels were
significantly less compared to controls (Fig.5). In cells treated with combination
of HIV-1+ ASH, Cocaine + ASH, METH + ASH, and as well as HIV-1 + Cocaine +
ASH and HIV-1 + METH + ASH, the MAP2 levels were reduced and comparable
with controls (Fig.5).

Dose response curve and Neuroprotective effects of Withanolide A
(WA)
There is a significant need for the development novel drugs using small molecules
that enhance and improve the memory and learning by influencing the cellular
pathways which have lasting disease modifying effects that could alleviate the
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Figure 6. Chemical structure of Withanolide A.
doi:10.1371/journal.pone.0112818.g006

course of neurodegenerative diseases such as AD. We have reported recently, that
Methanol: Chloroform (3:1) extract prepared from the dried roots of ASH, when
subjected to LC-MS analysis showed the presence of a major peak of Withanolide
A (WA), and the extract was neuroprotective against Ab induced cytotoxicity and
HIV-1 infection [24]. Since the major constituent ASH is WA, we wanted to see
whether purified WA (Cat # W2145, Sigma-Aldrich, Mol.Wt. 470.60, Purity
§95%), a C5, C6-epoxy steroidal lactone (Fig.6), exerts similar neuroprotective
effects. WA has been shown earlier to possess strong neuropharmacological
activities in promoting neurite outgrowth, reversing neuritic atrophy, and aiding
synapse reconstruction [20, 37, 38] and thus provides a strong pharmacological

Figure 7. Modulatory effects of Withanolide A and b-Amyloid1-42 on human neuronal cells. A. Doseresponse of Withanolide A showing growth-stimulatory effects in terms of % viability. B. MTT assay showing
the inhibition of cell viability by b-Amyloid1-42 and its reversal by Withanolide A at two concentrations on SK-NMC cells. The values were expressed as percentage of cell viability compared to control cells and are the
mean ¡ SD of four experiments. *** and ** indicates a statistically significant difference (p,0.0001) and
(p,0.0018) respectively compared to controls. WA – Withanolide A; b-AMY - b-Amyloid1-42
doi:10.1371/journal.pone.0112818.g007
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rationale for further investigation. Figure 7A shows the dose-response curve for
WA on SK-N-MC cells. WA exhibited a significant (p,0.0001) dose-dependent
increase in cell viability as reflected by MTT activity from 1.25 mg/ml
(0.267¡0.035) to 20 mg/ml (0.573¡0.5) compared to control (0.258¡0.035).
Figure 7B shows the histograms of cell viability in control, Ab, WA and Ab plus
WA treated cultures at two different WA concentrations. The results supported
the earlier observations that Ab exerts cytotoxic effects in neuronal cells with
decreased cell viability when tested individually. However, when WA was added to
Ab treated cultures, the cytotoxic effects of Ab were neutralized thus showing the
beneficial effects (Fig.7B).

Effects of WA on HIV-1 infection and drugs of abuse and MTT
assay
Neurodegenerative diseases commonly induce irreparable damage of central
nervous system (CNS) neuronal networks, resulting in permanent functional
impairments. Effective medications against neurodegenerative diseases are
currently lacking. Neuroprotective properties of ASH are attributed to withanolides, particularly WA and therefore WA forms important candidate for the
therapeutic treatment of neurodegenerative diseases like Alzheimer’s disease.
Further, WA is one of the most commonly found and extensively studied active
ingredients of ASH and has attracted interest due to its strong neuropharmacological properties of promoting outgrowth and synaptic reconstruction
[20, 37, 38]. Accordingly, the effects of WA were tested on SK-N-MC cells in order
to understand the beneficial effects and see whether WA could protect cells from
HIV-1 infection as well as during the exposure to drugs of abuse. Figure 8 shows
the histograms of % cell viability in control, HIV-1, Cocaine, Methamphetamine,
WA, in cells treated individually and in combination. The levels of % cell viability
were significantly decreased (p,0.0001) in cells infected with HIV-1and as well as
in cells treated with Cocaine and METH compared with the untreated control
cells (Fig.8). In plain WA treated cells the % cell viability level was significantly
elevated (p,0.0001) compared to control (Fig.8). In cells treated with
combination of HIV-1+ WA, Cocaine + WA, Meth + WA, as well as HIV-1 +
Cocaine + WA and HIV-1 + Meth + WA the % cell viability levels were relatively
increased and comparable with controls (Fig.8).

Discussion
Considerable attention has been focused on the accumulation of b-amyloid
peptide (Ab) within the brain as a major etiologic factor in the pathogenesis of
Alzheimer disease (AD). At present, there is no curative treatment available for
AD and the approved medications are used only for slowing the disease
progression or providing prophylaxis. Numerous studies over the past two
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Figure 8. Protective effects of Withanolide A from HIV-1Ba-L (clade B) infection, Cocaine and METH
treated in SK-N-MC cells. MTT assay showing the inhibition of % cell viability in HIV-1Ba-L (clade B), Cocaine
and METH treated and their reversal by Withanolide A. Withanolide A alone showed significant increase in
cell viability. The values were expressed as percentage of cell viability compared to control cells and are the
mean ¡ SD of four experiments. ***, **, * indicates a statistically significant difference (p,0.0001),
(p,0.0006), and (p,0.0185), respectively compared to controls. WA–Withanolide A; CO, COC – Cocaine;
METH – Methamphetamine.
doi:10.1371/journal.pone.0112818.g008

decades indicated that ASH has anti-inflammatory, anti-tumor, anti-stress, antioxidant, mind boosting and rejuvenating properties [35, 36]. Studies also showed
that extracts of ASH promote dendrite formation in human neuroblastoma cells
in vitro in a dose-dependent manner [37]. In our earlier studies, ASH extract
showed growth stimulatory effects at relatively lower concentrations on SK-NMC, a neuronal cell line [24]. Accordingly, this extract was utilized for
identification of the components present as well as for other studies. HPLC and
mass spectra analysis showed the presence of withanolide A as the main
withanolide in the extract [24]. Withanolides, more particularly WA are known to
be responsible for the multiple medicinal properties of ASH [38].
Many studies have utilized in vitro models to evaluate the toxicity and
neurodegeneration in cells treated with Ab, still, there is lack of information
regarding the mechanisms involved during the neurodegenerative processes. In
the present study, the Ab treated cells, when stained with trypan blue showed
several positive cells indicating cell death and cytotoxic effects compared to plain
controls (Fig.1A and Fig.1B). However, when ASH was added to Ab treated
cultures, the cytotoxic effects of Ab were neutralized (Fig.1D) and the cells were
comparable to plain (Fig.1A) and ASH (Fig.1C) treated controls, suggesting the
chemopreventive or protective effects of ASH against Ab induced toxicity.
Toxicity mediated by excitatory amino acids (EAAs) is a well-documented
mechanism of neurodegeneration that has also been postulated to function in Abinduced toxicity [39, 40]. It is possible that similar mechanisms may be
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responsible for the cell degeneration observed in the present study during the
exposure of Ab.
Accumulating evidence from different clinical studies, transgenic models as well
as in vitro studies suggests that intra-neuronal accumulation of Ab as an early
event that plays an important role in the pathogenesis of AD [41]. Further,
extracellular addition of Ab to neuronal cells in culture is known to induce the
uptake of Ab and its localization to the nucleus [42, 43]. In our study, cultures
treated with Ab alone (Fig.2B) showed much more marked internalization of the
toxic peptide compared to cultures treated with Ab plus ASH (Fig.2D). The plain
(Fig.2A) and ASH (Fig.2C) controls showed background stain. It is likely that
enhanced accumulation of Ab in neuronal cells might potentiate the peptide’s
toxic effects and were counteracted by ASH as observed earlier, confirming the
neuro-protective effects of ASH.
In cell culture models, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT), is widely used to elucidate the cellular toxicity of the Ab peptide.
It is generally believed that inhibition of MTT reduction by Ab is an early
indication of the Ab-induced impairment of the cellular reducing activity.
Further, it has recently been reported that Ab inhibits cellular MTT reduction by
enhancing MTT formazan exocytosis rather than by inhibiting MTT reduction
directly [31, 32]. In this study, on microscopic examination, SK-N-MC cells
treated with Ab and incubated with MTT showed marked appearance of needlelike exocytosed formazan crystals on the cell surface (Fig.3B) compared with the
intracellular even formazan granules seen in the untreated control cells (Fig.3A).
Also both the Ab plus ASH (Fig.3D) as well as plain ASH (Fig.3C) treated cells
showed intracellular even formazan granules indicating the protective and reversal
effect of ASH on MTT exocytosis. These observations suggest that Ab enhances
MTT formazan exocytosis probably through an intracellular signal transduction
pathway which is attenuated by ASH.
Increasing evidence suggests that Ab has a direct influence on cholinergic
activity. Acetylcholinesterase activity is increased in plaques and tangles very early
in the process of amyloid deposition. In particular, Ab has been shown to induce
the expression of acetylcholinesterase in the brains of CT-100-expressing
transgenic mice and in cell culture experiments indicating a link between Ab
production and acetylcholinesterase activity. In our study, the results demonstrated that exposure of SK-N-MC cells to Ab resulted in a significant (p,0.0001)
increase in acetylcholinesterase activity (Fig.4) indicating cytotoxicity compared
to controls. However, ASH plus Ab treated cultures showed protective effects
against the cytotoxicity as the levels of acetylcholinesterase activity were
comparable with plain and ASH treated controls (Fig.4). It has been reported that
Ab enhances acetylcholinesterase activity by increasing calcium entry through Ltype voltage-dependent calcium channels [44], suggesting that increase may be a
consequence of a disturbance of calcium homeostasis.
Brain deposition of Ab is a common pathologic feature in HIV positive
patients. An increased prevalence of amyloid plaques was observed in cortex of the
brains of AIDS patients compared with the age matched controls [45]. Several
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reports have shown an increase in the amyloid deposition in brains of HIV-1
infected patients [46–48]. Further, HIV-1 associated neurocognitive disorders
(HAND) in elderly is associated with b-amyloidosis and that the Ab accumulation
reflects the clinical outcome of HIV-1 infection [49]. Due to higher survival rates
after antiretroviral therapy (ART), several factors including aging, HIV-1
infection, and secondary effects of ART contribute to brain Ab deposition and
further to AD. Illicit or drugs of abuse such as Methamphetamine (METH), and
Cocaine are powerful psycho-stimulants that are widely abused in USA and all
over the world and are significant risk factors for HIV-1 infection and AIDS
disease progression [50]. Accordingly, both, HIV-1 infection and drugs of abuse
contribute to the amyloid deposition in the brain and associated neurocognitive
disorders and impacts in neurodegeneration. In the present study, the levels of
MAP2 were significantly increased in cells infected with HIV-1and as well as in
cells treated with Cocaine and METH compared with untreated control cells
(Fig.5). In plain ASH treated cells the MAP2 levels were significantly less
compared to controls. In cells treated with combination of HIV-1+ ASH, Cocaine
+ ASH, METH + ASH, and as well as HIV-1 + Cocaine + ASH and HIV-1 +
METH + ASH, the MAP2 levels were reduced and comparable with controls
(Fig.5). It is known that increased levels of MAP2 induces neuronal differentiation
and can profoundly affect cell cycle progression and further induce apoptosis [34]
and accordingly contribute to neurodegeneration. ASH and its constituents
showed various beneficial effects against models of Alzheimer’s disease and spinal
cord injury. ASH extracts also showed ameliorative effects against other
neurodegenerative disease models such as Parkinson’s disease and Huntington’s
disease suggesting that ASH may be useful against various neurodegenerative
diseases. The reduction in the levels of MAP2 in ASH treated cells and further
decreasing the levels in HIV-1 infected and drugs of abuse treated cells suggests
that ASH could be a potential novel drug to reduce the brain amyloid burden and/
or improve the HIV-1 associated neurocognitive impairments.
ASH is recommended as ‘‘Medhya-Rasayana’’ (memory and intellect
enhancers) in the ayurvedic traditional Indian medicinal system [51]. We have
reported recently, that Methanol: Chloroform (3:1) extract prepared from the
dried roots of ASH, when subjected to LC-MS analysis showed the presence of a
major peak of Withanolide A (WA). Further, this ASH extract showed
neuroprotective effects against b-amyloid induced cytotoxicity, HIV-1 infection,
as well as drugs of abuse. Since the major constituent ASH is WA, we wanted to
see whether purified WA (Cat # W2145, Sigma-Aldrich, Mol.Wt. 470.60, Purity
§95%), a C5, C6-epoxy steroidal lactone (Fig.6), exerts similar neuroprotective
effects. WA has been shown earlier to possess strong neuropharmacological
activities in promoting neurite outgrowth, reversing neuritic atrophy, and aiding
synapse reconstruction [20, 37, 38] and thus provides a strong pharmacological
rationale for further investigation. Figure 8 shows the histograms of % cell
viability in control, HIV-1, Cocaine, Methamphetamine, WA, in cells treated
individually and in combination. The levels of % cell viability were significantly
decreased (p,0.0001) in cells infected with HIV-1and as well as in cells treated
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with Cocaine and METH compared with the untreated control cells (Fig.8). In
plain WA treated cells the % cell viability level was significantly elevated
(p,0.0001) compared to the control. In cells treated with combination of HIV-1+
WA, Cocaine + WA, Meth + WA, as well as HIV-1 + Cocaine + WA and HIV-1 +
Meth + WA the % cell viability levels were relatively increased and comparable
with controls (Fig.8). These results suggest that WA has a potential basis for novel
drugs against neurodegenerative diseases. However, direct target molecules of WA
have not been identified clearly as yet. According to the ‘‘amyloid cascade
hypothesis’’, a chronic imbalance between the production and clearance of Ab
results in the formation of Ab plaques and plays a major role in the
etiopathogenesis of AD [52]. Ab is generated via cleavage of the amyloid –b
precursor protein (AbPP). The proteolytic processing of AbPP takes place by
sequential cleavage by various proteases namely, a-, b-, and c-secretase. It has
been reported that b-secretase (BACE1) is up-regulated significantly in the AD
brains and that WA significantly downregulated BACE1 levels in primary rat
cortical neurons [53]. BACE1 is a rate-limiting enzyme in the production of Ab
and it has been reported that a slight increase in BACE1 levels leads to a dramatic
increase in the production of Ab 40/42 [54, 55]. Accordingly, it is possible that
even a slight decrease in BACE1 levels may lead to a considerable decrease in the
production of Ab. Thus, WA with its substantial inhibitory activity against BACE1
may form a potentially effective novel compound for AD treatment by decreasing
Ab generation and deposition. Thus, modulation of one or more Ab-degrading
enzymes may prove vital in the prevention and treatment of AD.
Even though, the mechanisms of AD are still not completely understood, it is
believed that excessive accumulation of Ab through abnormal b-amyloid
precursor protein (AbPP) and Ab metabolism are key events in the pathogenesis
of AD. Thus, strategies targeting Ab metabolism and AbPP processing are of
immense help for the treatment and prevention of AD. Here we have
demonstrated that ASH extract reverses the Ab induced neuronal toxicity in SKN-MC cells and may serve as a potential therapeutic agent for use in AD and
possibly in other HIV related disorders involving memory deficiency (Fig.9).
Some studies suggest that one pathway of Ab induced cytotoxicity could be
mediated by free radicals and oxidative stress [29]. It is known that ASH has
antioxidant and free radical scavenger activity and this could inhibit Ab induced
cellular degeneration. Also, ASH reverses acetylcholinesterase activity and thus has
potential to modulate cholinergic function or may be connected to clearing effect
associated with the degradation of Ab by many proteases, including neprilysin,
endothelin-converting enzyme, angiotensin-converting enzyme, plasminogen
activator and matrix metalloproteinase-9 [56–60]. ASH extract used in the present
study is known to contain several compounds besides withanolide A. However, it
is reasonable to expect that appropriate combinations of multiple chemopreventive components might provide greater efficacy than the administration of
individual component. It is unlikely that chemoprevention of AD can be achieved
by a single agent. Accordingly, there is need to develop a mixed cocktail approach
with multiple herbal ingredients that act in a concerted way and produce multiple
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Figure 9. A comprehensive model showing the b-Amyloid, HIV-1Ba-L (clade B) as well as drugs of abuse
induced degenerative changes in SK-N-MC neuronal cells and their reversal by Ashwagandha (ASH)
and Withanolide A (WA). Red and Blue arrows indicate increase in degenerative changes by b-Amyloid, HIV1 and Drugs of Abuse respectively. Green and Orange arrows indicates reversal of degenerative changes by
ASH and WA.
doi:10.1371/journal.pone.0112818.g009

cellular effects with further enhancement of the efficacy in a positive manner for
the effective management of AD. Further studies of ASH will probably contribute
to resolving an urgent unmet medical need involving efficacious treatments that
may offer a cure for neurodegenerative diseases. Studies are in progress from this
point of view.

Conclusions
In summary, this study demonstrated that Methanol: Chloroform (3:1) extract
prepared from the dried roots of ASH and comprising alkaloids and steroidal
lactones, the prominent being Withanolide A, was neuroprotective against Abinduced cytotoxicity. This observation was supported by trypan blue staining of
the dead cells, cellular localization, MTT formazan exocytosis, levels of
acetylcholinesterase activity and % cell viability confirming the chemopreventive
or protective effects of ASH against Ab induced toxicity (Fig.9). Further, the
reduction in the levels of MAP2 in ASH treated cells and decreasing its levels in
HIV-1 infected and drugs of abuse treated cells suggests that ASH could be a
potential novel drug to reduce the brain amyloid burden and/or improve the
HIV-1 associated neurocognitive impairments (Fig.9). The studies carried out
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with ASH purified constituent WA showed similar neuroprotective properties in
neuronal cells. These results further established that neuroprotective properties of
the ASH root extract observed in the present study may provide some explanation
for the ethnopharmacological uses of ASH in traditional medicine for cognitive
and other HIV associated neurodegenerative disorders.
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